1	Dramatic resurgence of malaria after 7 years of intensive vector control interventions in
2	Eastern Uganda
3	
4	*Moses R. Kamya <sup>1,2*</sup> , Joaniter I. Nankabirwa <sup>1,2</sup> , Emmanuel Arinaitwe <sup>1</sup> , John Rek <sup>1,3</sup> , Maato
5	Zedi <sup>1</sup> , Catherine Maiteki-Sebuguzi <sup>1,3</sup> , Jimmy Opigo <sup>3</sup> , Sarah G. Staedke <sup>4</sup> , Ambrose Oruni <sup>4</sup> ,
6	Martin J. Donnelly <sup>4</sup> , Bryan Greenhouse <sup>5</sup> , Jessica Briggs <sup>5</sup> , Paul J. Krezanoski <sup>5</sup> , Teun Bousema <sup>6</sup> ,
7	Philip J. Rosenthal <sup>5</sup> , Peter Olwoch <sup>1</sup> , Prasanna Jagannathan <sup>7</sup> , Isabel Rodriguez-Barraquer <sup>5</sup> ,
8	Grant Dorsey <sup>5</sup>
9	
10	
11	<sup>1</sup> Infectious Diseases Research Collaboration, Kampala, Uganda.
12	<sup>2</sup> School of Medicine, Makerere University Kampala, Uganda.
13	<sup>3</sup> National Malaria Control Division, Ministry of Health, Kampala, Uganda,
14	<sup>4</sup> Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United
15	Kingdom,
16	<sup>5</sup> Department of Medicine, University of California San Francisco, San Francisco, California,
17	USA.
18	<sup>6</sup> Department of Medical Microbiology, Radboud University Medical Center, Netherlands
19	<sup>7</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford
20	University, USA.
21	
22	*Corresponding author: Moses R. Kamya. Email: <u>mkamya@idrc-uganda.org</u> Tel:
23	+256776520469
24	Key words: malaria, effective malaria control, resurgence, long-lasting insecticidal nets (LLINs),
25	indoor residual spraying of insecticide (IRS), clothianidin, pirimiphos-methyl
26	Short title: Malaria resurgence despite intensive control interventions in Uganda

#### 27 Abstract

Background: Tororo District, Uganda experienced a dramatic decrease in malaria burden from 28 2015-19 following 5 years of indoor residual spraying (IRS) with carbamate (Bendiocarb) and 29 30 then organophosphate (Actellic) insecticides. However, a marked resurgence occurred in 2020, which coincided with a change to a clothianidin-based IRS formulations (Fludora 31 32 Fusion/SumiShield). To quantify the magnitude of the resurgence, investigate causes, and 33 evaluate the impact of a shift back to IRS with Actellic in 2023, we assessed changes in malaria metrics in regions within and near Tororo District. 34 35 Methods: Malaria surveillance data from Nagongera Health Center, Tororo District was included from 2011-2023. In addition, a cohort of 667 residents from 84 houses was followed 36 from August 2020 through September 2023 from an area bordering Tororo and neighboring 37 38 Busia District, where IRS has never been implemented. Cohort participants underwent passive 39 surveillance for clinical malaria and active surveillance for parasitemia every 28 days. Mosquitoes were collected in cohort households every 2 weeks using CDC light traps. Female 40 Anopheles were speciated and tested for sporozoites and phenotypic insecticide resistance. 41 Temporal comparisons of malaria metrics were stratified by geographic regions. 42 Findings: At Nagongera Health Center average monthly malaria cases varied from 419 prior to 43 implementation of IRS; to 56 after 5 years of IRS with Bendiocarb and Actellic; to 1591 after the 44 45 change in IRS to Fludora Fusion/SumiShield; to 155 after a change back to Actellic. Among cohort participants living away from the border in Tororo, malaria incidence increased over 8-46 fold (0.36 vs. 2.97 episodes per person year, p<0.0001) and parasite prevalence increased over 47 4-fold (17% vs. 70%, p<0.0001) from 2021 to 2022 when Fludora Fusion/SumiShield was used. 48 Incidence decreased almost 5-fold (2.97 vs. 0.70, p<0.0001) and prevalence decreased by 39% 49 (70% vs. 43%, p<0.0001) after shifting back to Actellic. There was a similar pattern among 50 51 those living near the border in Tororo, with increased incidence between 2021 and 2022 (0.93

52 vs. 2.40, p<0.0001) followed by a decrease after the change to Actellic (2.40 vs. 1.33, p<0.001). 53 Among residents of Busia, malaria incidence did not change significantly over the 3 years of observation. Malaria resurgence in Tororo was temporally correlated with the replacement of 54 An. gambiae s.s. by An. funestus as the primary vector, with a marked decrease in the density 55 56 of An. funestus following the shift back to IRS with Actellic. In Busia, An. gambiae s.s. remained 57 the primary vector throughout the observation period. Sporozoite rates were approximately 50% higher among An. funestus compared to the other common malaria vectors. Insecticide 58 59 resistance phenotyping of An. funestus revealed high tolerance to clothianidin, but full 60 susceptibility to Actellic. Conclusions: A dramatic resurgence of malaria in Tororo was temporally associated with a 61 change to clothianidin-based IRS formulations and emergence of An. funestus as the 62 predominant vector. Malaria decreased after a shift back to IRS with Actellic. This study 63 64 highlights the ability of malaria vectors to rapidly circumvent control efforts and the importance of high-quality surveillance systems to assess the impact of malaria control interventions and 65 generate timely, actionable data. 66

67

### 69 Introduction

Between 2000 and 2015 it was estimated the incidence of malaria in Sub-Saharan Africa 70 decreased by 40%, with the scale up of vector control interventions responsible for the majority 71 72 of cases averted.(1) However, since 2015 progress has stalled and even reversed course in 73 some of the highest burden countries of Africa.(2) Indeed, the global burden of malaria has 74 become increasingly concentrated in Africa, which accounted for over 94% of cases and 96% of deaths in 2022.(2) Turning the tide on malaria will require a better understanding of the root 75 76 causes of stalled progress, better use of local data to inform policy decision making, and a more 77 flexible and targeted approach to control interventions.(3)

78

79 Uganda is emblematic of other high burden African countries, where progress in reducing the 80 burden of malaria has been slow and difficult to sustain despite the scale up of proven control 81 interventions. Uganda was the first country to implement universal distribution of free longlasting insecticidal nets (LLINs) starting in 2014, with repeated campaigns every 3-4 years. 82 Uganda also has one of the largest indoor residual spraying of insecticide (IRS) programs, 83 focusing on selected high transmission districts using different formulations of insecticides 84 85 rotated every few years. The success of this intensive approach to vector control has been well documented in Tororo District, a historically high transmission area of southeastern Uganda, 86 where our group has been conducting comprehensive cohort-based malaria surveillance studies 87 since 2011.(4) IRS was first implemented in Tororo District in December 2014, initially using a 88 89 carbamate (Bendiocarb), then switching to an organophosphate (Actellic) in 2016. Comparing key malaria indicators measured from 2011-14, prior to IRS, with indicators in 2017-19, after two 90 rounds of universal LLIN distribution and 5 years of sustained IRS, we documented a 500-fold 91 92 decrease in malaria transmission intensity, a 60-fold decrease in the incidence of symptomatic 93 malaria, and a 5-fold decrease in parasite prevalence among children 0.5-10 years of age.(5) In addition, over this time frame there was a marked shift in the predominant vector species from 94

*An. gambiae s.s.* to *An. arabiensis*. However, following a change to clothianidin-based
formulations of IRS in 2019-20, a marked resurgence of malaria cases was documented using
health facility-based data from 5 districts of Uganda (including Tororo), reaching pre-IRS levels
within 1-2 years.(6)

99

To better quantify the magnitude of the malaria resurgence in Tororo and to investigate potential causes, we compared temporal changes in malaria incidence, prevalence, and entomological measures between September 2020 and September 2023 in a cohort of 667 residents living in two areas within Tororo District and in neighboring Busia District, where IRS has never been implemented. In addition, we assessed changes after the formulation of IRS in Tororo District was shifted back to an organophosphate in March 2023.

106

### 107 Methods

# 108 Study setting and population level vector control interventions

109 Our team has conducted a series of comprehensive cohort-based malaria surveillance studies (referred to as PRISM) in southeastern Uganda starting in October 2011 (Figure 1). Briefly, the 110 111 "PRISM 1" study was conducted from October 2011 – September 2017 and the "PRISM 2" study conducted from October 2017 – October 2019 in Nagongera subcounty, Tororo District.(5) 112 The "PRISM Border Cohort" study (the focus of this report) was conducted from August 2020 – 113 114 September 2023 in both Tororo District and neighboring Busia District. Tororo is historically a 115 high malaria transmission district with an estimated entomological inoculation rate (EIR) of 310 infective bites per person per year in 2011-12.(7) Prior to 2013, vector control in Tororo District 116 was limited to the distribution of LLINs through antenatal care services. In November 2013, 117 118 universal distribution of free LLINs was conducted as part of a national campaign, and similar 119 campaigns were repeated in May 2017 and June 2020. All LLIN distribution campaigns in Tororo District utilized standard pyrethroid LLINs. IRS with the carbamate (Bendiocarb) was 120

121 introduced for the first time in Tororo in December 2014–January 2015, with additional rounds 122 administered in June–July 2015 and November–December 2015. In June–July 2016, the IRS compound was changed to an organophosphate (Actellic), with repeated rounds in June–July 123 124 2017, June–July 2018, and March–April 2019. The IRS program changed to clothianidin-based 125 formulations in 2020, with Fludora Fusion (clothianidin + deltamethrin) administered in March 126 2020 and March 2021, and SumiShield (clothianidin alone) administered in March 2022. In March 2023, a decision was made to shift back to IRS with Actellic in response to the 127 128 resurgence of malaria. Busia is a high malaria transmission district bordering Tororo District to 129 the south. As in Tororo, prior to 2013 vector control in Busia District was limited to targeted distribution of LLINs through antenatal care services. Universal distribution of free LLINs were 130 conducted in Busia District in May 2013, May 2017, and December 2020. The first two LLINs 131 132 distribution campaigns in Busia District utilized standard pyrethroid LLINs and the third 133 campaign utilized LLINs containing deltamethrin plus piperonyl butoxide (PermaNet 3.0). IRS 134 has never been implemented in Busia District.

135

## 136 Routine health facility-based malaria surveillance data

137 To provide context, we illustrate continuous trends in disease burden from October 2011 – September 2023 at Nagongera Health Center IV, Tororo District (Figure 2). This health center is 138 part of a national health facility-based malaria surveillance network that provides high-quality 139 data to monitor geographic and temporal trends in malaria burden and assess the impact of 140 141 population level control interventions.(6) Briefly, routine individual level data are collected from all patients who present to the outpatient departments, including the number of laboratory 142 confirmed cases of malaria. Since November 2018, after mapping of the region, we have been 143 144 able to estimate the incidence of malaria from a target area around Nagongera Health Center 145 IV, defined as the number of cases of laboratory-confirmed malaria diagnosed at the health

center among patients residing in the target area, per unit time, divided by the total population ofthe target area.

148

## 149 Screening and enrollment of households into the cohort study

150 Screening and enrollment of households and study participants was previously described.(8) 151 Briefly, in May 2020, all households in a contiguous study area including two sub-counties in Tororo District and one sub-county in Busia District were enumerated and mapped using 152 153 handheld global positioning systems (Garmin e-Trex 10 GPS unit, Garmin International Inc., 154 Olathe, KS) to provide a sampling frame for recruitment of households into the cohort study. Households were enrolled from three distinct geographic regions (Figure 1). In August 2020, 20 155 households from Busia District located 1.9-3.2 km from the border with Tororo District and 30 156 157 households from Tororo district located 0.7-3.5 km from the border (referred to as Tororo, near 158 border) were enrolled. Preliminary data revealed that malaria burden was surprisingly similar between houses in Busia District and those in Tororo near the border.(8) To capture more of a 159 gradient in transmission intensity, an additional 30 households from Tororo District located 5.5-160 10.8 km from the border (referred to as Tororo, away from border) were enrolled in January 161 162 2021. Households were randomly selected from our enumeration list for screening and enrolled if they met the following criteria: 1) having at least two members aged 5 years or younger; 2) no 163 more than 7 permanent residents currently residing; 3) no plans to move from the study 164 165 catchment area in the next 2 years; and 4) willingness to participate in entomological 166 surveillance studies. In March 2022, 4 households (3 from Busia and 1 from Tororo away from the border) were enrolled to replace households that had been withdrawn from the cohort study. 167 168

100

### 169 Screening, enrollment and follow-up of cohort participants

All permanent residents from enrolled households were screened and enrolled in the cohort
study if they met the following criteria: 1) the selected household was considered their primary

172 residence; 2) agreement to come to the study clinic for any febrile illness and scheduled routine 173 visits; 3) agreement to avoid antimalarial medications outside the study; and 4) provision of written informed consent (for parent or quardian in the case of children). The cohort was 174 dynamic, such that over the course of the study any permanent residents that joined a 175 176 household were screened for enrollment. At enrollment, a baseline evaluation was conducted 177 including a detailed medical history, focused physical examination, and blood collection by venipuncture for hemoglobin measurement, thick blood smear, and storage for future molecular 178 179 studies. A household survey was conducted to collect information on characteristics of the 180 household and LLIN ownership; all household members were provided access to an LLIN after the survey. A wealth index was generated for each household using principal components 181 analysis based on common assets and categorized into tertiles. Cohort study participants were 182 183 encouraged to come to a dedicated study clinic open 7 days per week for all their medical care. 184 Routine visits were conducted every 4 weeks and included a standardized evaluation and collection of blood by finger prick/heel stick (if < 6 months of age) or venipuncture (if aged 6 185 months and older) for thick blood smear, hemoglobin measurement (every 12 weeks), and 186 storage for future molecular studies. Study participants found to have a fever (tympanic 187 188 temperature >  $38.0^{\circ}$ C) or history of fever in the previous 24 hours at the time of any clinic visit had a thick blood smear read immediately. If the thick blood smear was positive by light 189 190 microscopy, the patient was diagnosed with malaria and managed according to national 191 guidelines. Study participants who missed their scheduled routine visits were visited at home 192 and requested to come to the study clinic as soon as possible. All enrolled participants were followed through September 30th, 2023 unless they were prematurely withdrawn. Participants 193 were withdrawn if they: 1) moved out of the cohort household; 2) were unable to be located for > 194 195 4 months; 3) withdrew informed consent; or 4) were unable to comply with the study schedule 196 and procedures.

197

#### 198 Laboratory evaluations

199 Thick blood smears were stained with 2% Giemsa for 30 minutes and evaluated for the 200 presence of asexual parasites. Parasite densities were calculated by counting the number of 201 asexual parasites per 200 leukocytes (or per 500, if the count was less than 10 parasites per 202 200 leukocytes), assuming a leukocyte count of 8,000/µL. A thick blood smear was considered 203 negative if examination of 100 high power fields revealed no asexual parasites. For quality control, all slides were read by a second microscopist, and a third reviewer settled any 204 205 discrepant readings. Quantitative PCR (gPCR) was performed at the time of enrollment, at each 206 routine visit (every 4 weeks), and when malaria was diagnosed. At each of these time points, DNA was extracted from approximately 200 µL of whole blood using Qiagen spin columns, and 207 extraction products were tested for the presence and quantity of *P. falciparum* DNA using a 208 209 highly sensitive qPCR assay targeting the multicopy conserved var gene acidic terminal 210 sequence with a lower limit of detection of 50 parasite/mL.(9)

211

#### 212 Entomological surveillance

Mosquito collections were conducted every 2 weeks in all rooms of study houses where cohort 213 214 study participants slept using CDC light traps positioned 1 m above the floor (Model 512; John W. Hock Company, Gainesville, Florida, USA). Traps were set at 7 PM and contents collected 215 216 at 7 AM the following morning. Entomology technicians assessed whether cohort study 217 participants reported sleeping under an LLIN each morning when trap contents were collected. 218 All female Anopheles were enumerated and identified taxonomically to species level based on 219 morphological criteria according to established taxonomic keys.(10) Every 2 weeks, up to 30 220 mosquitoes identified as from the An. gambiae s.l. complex from each of the 3 study sites were 221 randomly selected for PCR analysis to distinguish An. gambiae s.s. from An. arabiensis.(11) All female Anopheles mosquitoes were stored in desiccant and up to 50 mosquitoes per CDC light 222 trap collection were assessed for sporozoites using ELISA.(12) 223

### 225 Insecticide resistance phenotyping

Insecticide resistance testing was performed using field caught mosquitoes collected from 226 227 neighboring Mayuge district to compare the response of both An. funestus s.l. and An. gambiae 228 s.l. to clothianidin and pirimiphos-methyl. Blood fed indoor-resting mosquitoes were collected in 229 May 2023 using a Prokopack electric aspirator, kept for 3-4 days, and then made to lay eggs by forced-egg laying.(13) The F1 progeny were reared and then used for bioassays using CDC 230 231 bottles for clothianidin and WHO tubes for pirimiphos-methyl at the standard diagnostic dose as 232 per WHO protocol.(14) Mosquitoes were exposed at different times to assess the time response curve for both species and then kept for 5 days post exposure to clothianidin and 1 day post 233 exposure to pirimiphos-methyl to assess delayed mortality. 234

235

### 236 Data analyses

All data were collected using standardized case record forms and double-entered using 237 Microsoft Access (Microsoft Corporation, Redmond, Washington, USA). Analyses were 238 performed using Stata, version 14 (Stata Corporation, College Station, Texas, USA). The 239 240 primary objective of the study was to compare temporal trends in key malaria metrics in the context of population level vector control interventions stratified by 3 geographic regions: 1) 241 Tororo, away from border, 2) Tororo, near border, and 3) Busia (Figure 1). The incidence of 242 243 symptomatic malaria was defined as the number of incident cases of malaria (fever plus a 244 positive thick blood smear by microscopy) divided by the person time of observation. Episodes of malaria occurring within 10 days of a prior episode were not considered incident events. The 245 prevalence of microscopic parasitemia was defined as the proportion of routine visits conducted 246 247 every 4 weeks in which asexual parasites were detected by microscopy. When estimating the 248 prevalence of microscopic or sub-microscopic parasitemia, samples that were positive by gPCR but negative by microscopy were added to the numerator. Vector density was defined as the 249

250 number of female Anopheles collected (stratified by species) divided by the number CDC light trap collections. The number of An. gambiae s.s. and An. arabiensis collected were estimated 251 252 by multiplying the observed proportions using the subset tested with species PCR by the total 253 number of An. gambiae s.l. collected stratified by each 2-week collection period and geographic 254 region. Selected comparisons of measures of malaria incidence were made using mixed effects 255 generalized linear models with a negative binomial regression family, with person time of observation included as an offset, and random effects at the level of the individual. Selected 256 257 comparisons of measures of parasitemia at the time of routine visits were made using mixed 258 effects generalized linear models with a Poisson family and random effects at the level of the individual. Selected comparisons of measures of vector density were made using negative 259 binomial regression models with the number of CDC light trap collections included as an offset. 260 261 For all comparisons, a p-value < 0.05 was considered statistically significant.

262

# 263 Ethics approval and informed consent

Ethical approval was obtained from the Makerere University School of Medicine Research and Ethics Committee (REF 2019–134), the Uganda National Council for Science and Technology (HS 2700), the London School of Hygiene & Tropical Medicine Ethics Committee (17777), and the University of California, San Francisco Committee on Human Research (257790). Written informed consent was obtained for all participants prior to enrolment into the cohort study.

269

#### 270 Results

## 271 **Temporal changes in malaria burden from Nagongera Health Center**

Data on temporal changes in malaria burden from Nagongera Health Center (located in the interior of Tororo District) covering from approximately 3 years before until 9 years after the initiation of IRS are presented in Figure 2. From October 2011 – November 2014, prior to the implementation of IRS, an average of 419 laboratory confirmed cases were diagnosed each

276 month. After IRS was implemented, first with Bendiocarb (administered every 6 months) followed by Actellic (administered annually), there was a sharp decline in malaria burden, 277 reaching an average of 56 cases per month and an incidence of 25 episodes per 1000 person 278 279 years in the surrounding community from March 2019 - February 2020. After switching to 280 annual rounds of IRS with clothianidin-based formulations in March 2020, malaria burden 281 gradually began to increase. This increase accelerated after the 2nd round of Fludora Fusion in March 2021. From March 2022 – February 2023, following a round of SumiShield (the 3rd and 282 final round of clothianidin-based IRS) malaria burden reached an average of 1591 cases per 283 284 month and an incidence of 587 episodes per 1000 person years. Malaria burden declined sharply after switching back to IRS with Actellic in March 2023, reaching 155 cases and an 285 incidence of 71 episodes per 1000 person years in September 2023. 286

287

### 288 Characteristics of cohort households and study participants

A cohort study including 3 distinct geographic regions in Tororo and Busia districts was 289 290 designed to further characterize the resurgence of malaria and explore potential causes. Characteristics of the households and cohort participants at the time of enrollment are 291 292 presented in Table 1. Household characteristics unrelated to vector control interventions were 293 similar across the three geographic regions, with the exception of household wealth, as a higher 294 proportion of houses in Busia were in the poorest category compared to houses in Tororo. The proportion of houses that reported owning at least one LLIN at enrollment ranged from 30% in 295 296 Busia to 74% in Tororo, away from border. Adequate LLIN coverage (defined as 1 LLIN per 2 persons) was 19% and similarly low across the three geographic regions. All cohort households 297 were provided LLINs by the study team following enrollment and 90% of household residents 298 299 reported sleeping under an LLIN at the time of home assessments conducted every 2 weeks 300 over the course of follow-up, with no significant differences between the three geographic regions. As expected, no households in Busia reported receiving IRS 12 months prior to 301

- 302 enrollment or during the course of the study. Household coverage for the 4 annual rounds of
- 303 IRS conducted in Tororo district from 2020 (assessed at enrollment) through 2023 was 90-100%

304 within Tororo, near border and 80-100% within Tororo, away from border.

305

# **Table 1. Characteristics of households and cohort participants at enrolment**

		Tororo							
Characteristic		Away from	Near	Busia District					
		border	border						
Household characteristics									
Number of Households		31	30	23					
Residents per household, median (rang	ge)	7 (4-7)	7 (4-7)	5 (3-7)					
Type of bousing construction $n(\%)$	Traditional	20 (64.5)	18 (60.0)	13 (56.5)					
	Modern	11 (35.5)	12 (40.0)	10 (43.5)					
	Poorest	5 (16.1)	7 (23.3)	13 (56.5)					
Wealth category, n (%)	Middle	15 (48.4)	10 (33.3)	4 (17.4)					
	Least poor	11 (35.5)	13 (43.3)	6 (26.1)					
Number of rooms used for sleeping, me	edian (range)	2 (1-3)	2 (1-4)	1 (1-3)					
Number of sleeping spaces, median (ra	ange)	3 (2-4)	3 (2-4)	2 (2-6)					
IRS in the last 12 months, n (%)		29 (93.6)	30 (100)	0					
Households with at least 1 LLIN, n (%)		23 (74.2)	16 (53.3)	7 (30.4)					
Households with 1 LLIN per 2 persons,	n (%)	7 (22.6)	5 (16.7)	4 (17.4)					
	Participant ch	aracteristics							
Number of participants		246	235	186					
Female gender, n (%)		146 (59.4)	125 (53.2)	98 (52.7)					
Age in years, median (IQR)		11.1 (3.8-24.2)	9.2 (3.8-22.4)	8.5 (3.2-22.3)					
	< 5 years	83 (33.7)	81 (34.5)	68 (36.6)					
Age categories, n (%)	5-15 years	76 (30.9)	82 (34.9)	60 (32.3)					
	> 15 years	87 (35.4)	72 (30.6)	58 (31.2)					

307

# 308 **Temporal changes in the incidence of malaria**

Monthly trends over the entire observation period in the incidence of malaria among cohort participants of all ages are presented in Figure 3A stratified by geographic region. To allow for direct comparisons over time and in relationship to rounds of IRS, malaria incidence (stratified by geographic region and age categories) was quantified over 6-month time periods from April 2021 through September 2023 (Table 2). Among residents of all ages from Tororo, away from border, the incidence of clinical malaria remained below 0.5 episodes per person year (PY) for each of the first 7 months of observation from February-August 2021 before there was a sharp 316 increase, reaching over 4 episodes per PY in March 2022. The incidence remained above 2.2 317 episodes per PY for all months from April 2022 until Actellic was sprayed in March 2023, after which there was a sharp decline, reaching 0.2 episodes per PY in September 2023 (Figure 3A). 318 319 Comparing 6-month time periods from April–September following annual rounds of IRS, the 320 incidence of malaria increased over 8-fold between 2021 and 2022 (0.36 vs. 2.97, p<0.0001) 321 corresponding to the second and third rounds of IRS with clothianidin-based formulations, then decreased almost 5-fold between 2022 and 2023 (2.97 vs. 0.70, p<0.0001) following the shift 322 323 back to Actellic (Table 2). Among residents from Tororo, near border, the incidence of clinical 324 malaria increased over 2.5-fold between April-September of 2021 and 2022 (0.93 vs. 2.40, p<0.0001), then decreased almost 2-fold between 2022 and 2023 (2.40 vs. 1.33, p<0.0001). 325 Among residents of Busia, the incidence of malaria between April-September did not change 326 327 significantly from 2021 to 2022 to 2023. Across the 3 geographic regions, the incidence of 328 malaria was between 3 and 4 times higher in children compared to adults, and the temporal patterns described above were similar across different age categories (Table 2). Despite the 329 high burden of malaria in this study, only 4 of 2,266 episodes (0.2%) met WHO criteria for 330 severe malaria: 2 cases of severe anemia (Hb < 5.0 gm/dL) occurred in children with confirmed 331 332 sickle cell disease, one of whom died; 1 case of severe anemia occurred in a 1 year old child who recovered; and 1 case of jaundice occurred in a 3 year old child who recovered. 333

334

335

	Ago ostogom	6-month time periods following the 2 <sup>nd</sup> round of Fludora Fusion in Tororo district									
Study site	Age category	Apr 21 – Sep 21	Oct 21 – Mar 22	Apr 22 – Sep 22	Oct 22 – Mar 23	Apr 23 – Sep 23					
Incidence of clinical malaria = number of cases / person years of observation (episodes per person year)											
	All ages	34/95.5 (0.36)	197/95.2 (2.07)	289/97.3 (2.97)	260/94.8 (2.74)	64/91.9 (0.70)					
Tororo, owov from bordor	< 5 years	15/30.8 (0.49)	83/28.4 (2.92)	114/28.4 (4.01)	106/25.5 (4.16)	13/20.2 (0.64)					
Tororo, away ironi border	5-15 years	12/27.9 (0.43)	81/30.7 (2.64)	140/35.5 (3.94)	124/35.7 (3.47)	34/36.5 (0.93)					
	> 15 years	7/36.7 (0.19)	33/36.1 (0.91)	35/33.3 (1.05)	30/33.6 (0.89)	17/35.2 (0.48)					
	All ages	89/95.5 (0.93)	132/95.4 (1.38)	219/91.3 (2.40)	216/95.3 (2.27)	123/92.6 (1.33)					
Tororo, poor bordor	< 5 years	43/28.2 (1.53)	61/23.1 (2.64)	73/18.8 (3.89)	67/16.9 (3.96)	24/14.0 (1.72)					
Tororo, near border	5-15 years	38/35.2 (1.08)	58/40.2 (1.44)	116/42.3 (2.75)	123/47.6 (2.58)	78/47.4 (1.65)					
	> 15 years	8/32.2 (0.25)	13/32.1 (0.40)	30/30.3 (0.99)	26/30.7 (0.85)	21/31.3 (0.67)					
	All ages	70/54.9 (1.27)	59/55.2 (1.07)	97/64.8 (1.50)	109/62.9 (1.73)	93/60.8 (1.53)					
Rusia	< 5 years	30/16.6 (1.81)	18/15.1 (1.19)	30/15.8 (1.89)	30/13.5 (2.21)	21/11.5 (1.83)					
Dusia	5-15 years	31/19.3 (1.61)	33/22.2 (1.49)	56/28.5 (1.96)	65/30.0 (2.17)	58/30.6 (1.90)					
	> 15 years	9/19.1 (0.47)	8/17.9 (0.45)	11/20.4 (0.54)	14/19.4 (0.72)	14/18.7 (0.75)					
	Prevalence of microscopic parasitemia at the time of routine visits performed every 4 weeks										
	All ages	61/1177 (5.2%)	213/1255 (17.0%)	346/1209 (28.6%)	384/1250 (30.7%)	227/1145 (19.8%)					
Tororo, away from border	< 5 years	9/374 (2.4%)	60/380 (15.8%)	97/351 (27.6%)	88/343 (25.7%)	29/255 (11.4%)					
Tororo, away nom border	5-15 years	33/341 (9.7%)	91/399 (22.8%)	157/444 (35.4%)	188/475 (39.6%)	143/451 (31.7%)					
	> 15 years	19/462 (4.1%)	62/476 (13.0%)	92/414 (22.2%)	108/432 (25.0%)	55/439 (12.5%)					
	All ages	323/1325 (24.4%)	318/1139 (27.9%)	503/1266 (39.7%)	472/1143 (41.3%)	436/1259 (34.6%)					
Tororo, poor bordor	< 5 years	63/387 (16.3%)	62/275 (22.5%)	98/262 (37.4%)	74/205 (36.1%)	49/188 (26.1%)					
Tororo, riear border	5-15 years	203/492 (41.3%)	200/483 (41.4%)	307/587 (52.3%)	312/574 (54.4%)	291/654 (44.5%)					
	> 15 years	57/446 (12.8%)	56/381 (14.7%)	98/417 (23.5%)	86/364 (23.6%)	96/417 (23.0%)					
	All ages	121/662 (18.3%)	145/794 (18.3%)	185/772 (24.0%)	195/858 (22.7%)	195/721 (27.0%)					
Pueie	< 5 years	28/198 (14.1%)	22/221 (10.0%)	32/188 (17.0%)	32/187 (17.1%)	29/137 (21.2%)					
Dusia	5-15 years	67/235 (28.5%)	94/319 (29.5%)	119/345 (34.5%)	117/406 (28.8%)	120/359 (33.4%)					
	> 15 years	26/229 (11.4%)	29/254 (11.4%)	34/239 (14.2%)	46/265 (17.4%)	46/225 (20.4%)					
Pr	evalence of microscop	ic or sub-microscopic	parasitemia at the time	of routine visits perfo	rmed every 4 weeks						
	All ages	195/1177 (16.6%)	593/1255 (47.3%)	843/1209 (69.7%)	853/1250 (68.2%)	487/1145 (42.5%)					
Tororo, owov from bordor	< 5 years	42/374 (11.2%)	158/380 (41.6%)	238/351 (67.8%)	232/343 (67.6%)	79/255 (31.0%)					
Tororo, away from border	5-15 years	79/341 (23.2%)	229/399 (57.4%)	339/444 (76.4%)	335/475 (70.5%)	215/451 (47.7%)					
	> 15 years	74/462 (16.0%)	206/476 (43.3%)	266/414 (64.3%)	286/432 (66.2%)	193/439 (44.0%)					
	All ages	687/1325 (51.8%)	704/1139 (61.8%)	966/1266 (76.3%)	847/1143 (74.1%)	795/1259 (63.1%)					
Tarara naar bardar	< 5 years	141/387 (36.4%)	160/275 (58.2%)	200/262 (76.3%)	155/205 (75.6%)	99/188 (52.7%)					
Tororo, near border	5-15 years	329/492 (66.9%)	335/483 (69.4%)	487/587 (83.0%)	481/574 (83.8%)	464/654 (70.9%)					
	> 15 years	217/446 (48.7%)	209/381 (54.9%)	279/417 (66.9%)	211/364 (58.0%)	232/417 (55.6%)					
	All ages	306/662 (46.2%)	356/794 (44.8%)	429/772 (55.6%)	478/858 (55.7%)	413/721 (57.3%)					
Rusia	< 5 years	76/198 (38.4%)	73/221 (33.0%)	77/188 (41.0%)	81/187 (43.3%)	64/137 (46.7%)					
DUSIA	5-15 years	125/235 (53.2%)	180/319 (56.4%)	217/345 (62.9%)	249/406 (61.3%)	224/359 (62.4%)					
	> 15 years	105/229 (45.9%)	103/254 (40.6%)	135/239 (56.5%)	148/265 (55.8%)	125/225 (55.6%)					

336	Table 2. Tempora	al changes in measure	s of malaria burden	stratified by age	categories and study site

#### 338 **Temporal changes in parasite prevalence**

339 Temporal changes in parasite prevalence mirrored those seen for incidence. Among residents of all ages from Tororo, away from border, the prevalence of microscopic parasitemia remained 340 341 below 6% and the prevalence of microscopic or sub-microscopic parasitemia remained below 18% for each of the first 7 months of observation (February-August 2021) before there was a 342 sharp increase, reaching over 34% and 78%, respectively, in the year after the final round of 343 clothianidin-based IRS was administered (Figure 3B and 3C). After IRS was changed back to 344 Actellic in March 2023, there was a sharp decline in these measures, with parasitemia reaching 345 13% and 30%, respectively. Comparing 6-month time periods from April-September following 346 347 annual rounds of IRS, the prevalence of microscopic parasitemia increased over 5-fold (5% vs. 348 29%, p<0.0001) and the prevalence of microscopic or sub-microscopic parasitemia increased over 4-fold (17% vs 70%, p<0.0001) between April-September of 2021 and April-September of 349 2022. After spraying with Actellic, the prevalence of microscopic parasitemia decreased by 30% 350 351 (29% vs. 20%, p<0.0001) and the prevalence of microscopic or sub-microscopic parasitemia decreased by 39% (70% vs 43%, p<0.0001). Among residents from Tororo, near border, the 352 prevalence of microscopic parasitemia increased by 62% (24% vs. 40%, p<0.0001) and the 353 prevalence of microscopic or sub-microscopic parasitemia increased by 47% (52% vs. 76%, 354 355 p<0.0001) between April-September of 2021 and April-September of 2022. After spraying with Actellic, the prevalence of microscopic parasitemia decreased by 13% (40% vs. 35%, p=0.04) 356 and the prevalence of microscopic or sub-microscopic parasitemia decreased by 17% (76% vs. 357 63%, p<0.0001). Among residents from Busia, between April-September of 2021 and April-358 359 September of 2022 there were modest increases in the prevalence of microscopic parasitemia (18% vs. 24%, p=0.03) and microscopic or sub-microscopic parasitemia (46% vs. 56%, p=0.03), 360 and, in contrast to the areas in Tororo receiving IRS with Actellic, remained similarly high in 361 April-September of 2023. Across the 3 geographic regions, the prevalence of parasitemia was 362 363 highest among children 5-15 years of age and the temporal patterns described above were similar across different age categories. 364

### 366 **Temporal changes in entomological measures**

Among houses from Tororo, away from border, through December 2021 the predominant 367 species was An. arabiensis (71% of female Anopheles collected) followed by An. funestus 368 (14%) and An. gambiae s.s. (12%). After December 2021, An. funestus became the 369 predominant species, a trend that continued until after IRS was shifted back to Actellic in March 370 2023, when the density of An. funestus decreased sharply (Figure 4A). Between mid-2021 and 371 372 mid-2022, the density of An. funestus increased over 4-fold (0.2 vs 1.0 mosquitoes per collection, p<0.0001); this density then decreased over 10-fold (1.0 vs 0.08, p<0.0001) between 373 374 mid-2022 and mid-2023. During these same 6-month time periods, the densities of An. gambiae 375 s.s. and An. arabiensis decreased between 2021 and 2022, with no significant change from 376 2022 to 2023 (Table 3). Among houses from Tororo, near border, vector densities were initially more evenly distributed across the 3 major Anopheles species. After December 2021, An. 377 funestus became the predominant species until after the round of IRS with Actellic in March 378 2023, although the decrease in An. funestus was not as sustained as in houses away from the 379 380 border (Figure 4B, Table 3). In Busia, An. gambiae s.s. made up 73% of all female Anopheles 381 collected and was the predominant species throughout the observation period, with the 382 exception of June-August each year, when An. funestus was predominant (Figure 4C, Table 3). 383

Overall, sporozoite rates were approximately 50% higher among *An. funestus* (1.75%)

compared to *An. arabiensis* (1.16%) and *An. gambiae* s.s. (1.12%), with sporozoite rates

highest for *An. funestus* across all 3 geographic regions (Table 3). However, the study lacked

387 precision to evaluate temporal trends in the proportion of mosquitoes infected with sporozoites.

388

389

Study site	Anopheles species	6-month time periods following the 2 <sup>nd</sup> round of Fludora Fusion in Tororo district								•		
		Apr 21 – Sep 21 Oc		Oct 2	Oct 21 – Mar 22 Apr 2		22 – Sep 22 Oct 22 – Mar 23		Apr 23 – Sep 23		Sporozoite rate	
		N*	n (VD)*	N*	n (VD)*	N*	n (VD)*	N*	n (VD)*	N*	n (VD)*	(full study period)
Tororo,	An. gambiae s.s.	739	179 (0.2)		61 (0.09)		80 (0.1)		88 (0.1)		66 (0.09)	4/484 (0.83%)
away	An. arabiensis		919 (1.2)	740	713 518 (0.7) 419 (0.6) 32 (0.04) 732	732	327 (0.4)	728	379 (0.5)	740	434 (0.6)	31/2818 (1.10%)
from	An. funestus		170 (0.2)	113			749 (1.0)		757 (1.0)		56 (0.08)	43/2160 (1.99%)
border	Other anopheles		54 (0.07)			18 (0.02)		21 (0.03)		21 (0.03)	1/155 (0.65%)	
-	An. gambiae s.s.		769 (1.0)		276 (0.4)		604 (0.8)		222 (0.3)		298 (0.4)	35/5312 (0.66%)
l ororo,	An. arabiensis	750	1577 (2.1)	763 <sup>83</sup> 10	832 (1.1)	744	604 (0.8)	749	446 (0.6)	747	842 (1.1)	86/7194 (1.20%)
hear	An. funestus	750	1313 (1.8)		1024 (1.3)		2570 (3.5)		1196 (1.6)		1154 (1.5)	125/7978 (1.57%)
Dorder	Other anopheles		60 (0.08)		23 (0.03)		80 (0.1)		28 (0.04)		153 (0.2)	3/482 (0.62%)
	An. gambiae s.s.	007	2657 (6.7)	421 (1.1) 395 27 (0.07) 145 (0.4)		2042 (4.3)		728 (1.6)		1535 (3.3)	143/10500 (1.36%)	
Busia	An. arabiensis		259 (0.7)		27 (0.07)	470	320 (0.7)	460	92 (0.2)	470	128 (0.3)	13/1196 (1.09%)
	An. funestus	397	563 (1.4)		145 (0.4)	472	694 (1.5)	403	207 (0.4)	472	1107 (2.3)	62/2982 (2.08%)
	Other anopheles		19 (0.05)		5 (0.01)		16 (0.03)		12 (0.03)		27 (0.06)	2/114 (1.75%)

390 Table 3. Temporal changes in vector density stratified by Anopheles species and study site

\* N = number of CDC LT collections, n = number of female anopheles mosquitoes collected, VD = vector density (n/N)
 392

### 393 Insecticide resistance phenotyping

Time response curves for *An. funestus s.l.* exposed to clothianidin and pirimiphos-methyl (active ingredient in Actellic) showed high resistance to clothianidin, but full susceptibility to pirimiphosmethyl (Figure 5). *An. gambiae s.l.* showed susceptibility to clothianidin even at reduced exposure times but mild tolerance to pirimiphos-methyl when exposure time was decreased.

### 399 Discussion

400 The combination of repeated universal LLIN distribution campaigns and sustained IRS has been associated with marked reductions in the burden of malaria at several historically holoendemic 401 402 areas of Uganda, including Tororo District. (15) However, in 2020-21 malaria began to resurge in 403 these areas following a change in IRS from an organophosphate to clothianidin-based formulations.(6) In this study, we quantified this resurgence and investigated potential causes in 404 405 a cohort of residents of Tororo District, where IRS had been sustained since 2015, and neighboring Busia District, where IRS has never been implemented. In Tororo, resurgence of 406 malaria increased approximately 18 months after the change to annual rounds of clothianidin-407 408 based IRS formulations, reaching a malaria incidence in children of over 4 episodes as 409 compared to 0.5 episodes per year before the change, with over 75% of the population infected 410 with malaria parasites. This resurgence was temporally correlated the emergence of An. funestus as the predominant malaria vector. In addition, An. funestus had a higher rate of 411 412 infection with sporozoites compared to the other common malaria vectors and it exhibited high tolerance to clothianidin. Following a shift back to IRS with Actellic, the burden of malaria and 413 414 the density of An. funestus declined sharply in Tororo. In contrast, in Busia district the burden of malaria remained high and relatively stable throughout this period, with An. gambiae s.s. the 415 primary vector. 416

417

This study and others provide several lines of evidence to support a causal link between the change from an organophosphate (Actellic) to clothianidin-based (Fludora Fusion/SumiShield)

420 IRS formulations and the marked resurgence of malaria. First, the timing of the resurgence 421 corresponded to a shift in active ingredient from pirimiphos-methyl to clothianidin-based formulations similar to what has been documented in 4 other districts of Uganda.(6) Second, 422 423 the timing of the resurgence also corresponded with the emergence of An. funestus, which was 424 found to have high tolerance to clothianidin and relatively high sporozoite rates, which likely contributed to a marked increase in transmission intensity. Third, the burden of malaria and 425 density of An. funestus were sharply reduced when the formulation of IRS was shifted back to 426 427 Actellic, a formulation for which An. funestus was found to be fully susceptible. Finally, just a few kilometers away in the neighboring district of Busia, malaria burden remained relatively 428 429 unchanged, and the predominant vector was An. gambiae s.s., consistent with historical reports 430 from high transmission areas of Uganda.(16)

431

432 Clothianidin is a neonicotinoid insecticide, one of 4 chemical classes pregualified for use in IRS by the WHO. The two most widely used clothianidin-based IRS formulations have been 433 SumiShield<sup>TM</sup> (active ingredient clothianidin alone) and Fludora Fusion<sup>TM</sup> (active ingredients 434 clothianidin combined with deltamethrin, a pyrethroid), which were prequalified by the WHO in 435 2017 and 2018, respectively. In preparation for and following the subsequent rollout of 436 437 clothianidin-based IRS formulations in sub-Saharan Africa, several field-based studies demonstrated broad susceptibility of major Anopheles vector species to clothianidin, with 438 439 residual activity lasting up to 18 months.(17) In a study of wild pyrethroid resistant An. gambiae s.l. carried out in experimental huts in Benin from 2013-14, clothianidin caused high overall 440 441 mortality rates across a range of wall surfaces.(18) In studies of insectary reared and wild collected mosquitoes conducted from 2016-17 across Africa, An. gambiae s.l. from 14 countries 442 and An. funestus from 2 countries were widely susceptible to clothianidin.(19) Subsequent 443 studies of field populations of common Anopheles species from Kenya, Benin, and Cote d'Ivoire 444 445 also reported high mortality rates following exposure to clothianidin. (20, 21, 22, 23) It should be noted that clothianidin is slower acting than other commonly used insecticide classes, requiring 446

447 a longer holding period to fully assess post-exposure mortality. (18, 24, 25) Despite these encouraging reports, some recent data have suggested the existence of reduced susceptibility 448 to clothianidin among African vectors, as reported in this study. In a rural area of Cameroon 449 450 where neonicotinoids have been used for crop protection, field caught An. gambiae showed resistance to clothianidin. (26) In a study of laboratory susceptible and resistant laboratory 451 strains using a variety of wall surfaces, the potency of clothianidin was lower against An. 452 funestus compared to An. gambiae.(17) In a study from Cameroon, Malawi, Ghana, and 453 Uganda, field collected An. funestus were broadly susceptible to clothianidin, however, possible 454 cross-resistance was detected in mosquitoes with genetic mutations associated with metabolic 455 456 resistance.(27) Importantly, in the only other study of the clinical impact of clothianidin-based 457 IRS formulations, from Northern Zambia (where An. funestus is the primary vector) in 2019-20, IRS with Fludora Fusion had no impact on parasite prevalence, demonstrating, as in the current 458 459 study, a lack of clinically relevant efficacy of the insecticide.(28)

460

One of the most striking findings in this and previous studies conducted in Tororo District was 461 462 the dramatic shift in Anopheles species predominance following the implementation of different formulations of IRS. Prior to the implementation of IRS, the primary vector was An. gambiae s.s. 463 464 (74% of female Anopheles collected), followed by An. arabiensis (22%) and An. funestus (4%). After 5 years of IRS with Bendiocarb followed by Actellic, vector densities declined dramatically 465 466 with An. arabiensis making up 99% of female Anopheles collected.(29) Entomologic surveillance was not conducted in the area from November 2019 – August 2020, corresponding 467 468 to the period when IRS with Fludora Fusion was first implemented. However, just prior to the second round of Fludora Fusion, An. arabiensis remained the primary vector in houses away 469 from the border in Tororo with a mix of An. arabiensis and An. gambiae s.s. predominating in 470 houses near the border in Tororo and An. gambiae s.s. predominating in in houses on the Busia 471 472 side of the border. Although low levels of An. funestus were detected at baseline in all 3 geographic regions in this study, it was only just before the second round of clothianidin-based 473

IRS that this species emerged as the predominant vector in Tororo, corresponding to the
dramatic resurgence of malaria. Interestingly, in houses away from the border in Tororo, *An. arabiensis* again became the predominant species after IRS was shifted back to Actellic,
consistent with the trend previously seen when Actellic was used.

478

An. funestus has emerged as an increasingly important malaria vector in many parts of sub-479 Saharan Africa. In a systematic review of studies from east and southern Africa, the primary 480 481 vector shifted from An. gambiae s.l. between 2000 and 2010 to An. funestus between 2011 and 2021.(30) In addition, several studies have reported higher infection rates among An, funestus 482 483 relative to other Anopheles species.(30, 31, 32) An. funestus has rapidly developed insecticide resistance in many parts of Africa, (33, 34, 35, 36, 37) is highly anthropophilic, can survive 484 longer than other vectors, (38) and may have the ability to take multiple blood meals within each 485 486 gonotrophic cycle, (39) all factors that may have contributed to the increasing importance of this vector following the scale up vector control throughout Africa. 487

488

489 Our prospective cohort study design allowed for a detailed description of the dynamics and magnitude of clinically relevant measures of the malaria resurgence. The rapid increase in the 490 491 incidence of symptomatic malaria over a 6-9 month period was similar to historically high transmission areas of Uganda where IRS had been discontinued, (15, 40) suggesting that after 492 the 2<sup>nd</sup> round of Fludora Fusion there was little or no impact, even in a setting of high reported 493 utilization of LLINs. In addition, the peak incidence of malaria during the resurgence exceeded 494 495 that in children enrolled in another cohort study prior to the implementation of IRS in Tororo 496 District, an observation that was also documented using health facility-based data covering the 497 period from 2011 through 2023 presented in Figure 1 of this study. Not only did the resurgence affect children, but malaria incidence also reached relatively high levels in adults. These findings 498 499 suggest that the resurgence may have been compounded by a relative loss of naturally 500 acquired immunity to malaria following an extended period when malaria had been well

501 controlled. Despite this suggestion of loss of immunity, there was no evidence from our cohort 502 that there was a "excess" in the risk of severe forms of malaria, highlighting the importance of 503 prompt and effective treatment available 7 days a week at our study clinic. However, a nearby 504 hospital based study conducted during the malaria resurgence reported severe malaria affecting 505 older children with unusual presentations including high risks of prostration, jaundice, severe 506 anemia, and black water fever.(41)

507

508 This study was not without limitations. First, we used an observational study design, with measures of impact based on comparisons of temporal trends between districts; a cluster 509 510 randomized controlled trial would have better compared trends, but available resources did not 511 allow this design. Second, there may have been other contributing factors to the resurgence that we did not fully explore, including the dynamics of host immunity. Third, we may have 512 513 underestimated the overall burden of disease in the community during periods of resurgence, since our cohorts receive prompt treatment and close follow up. Fourth, entomological data 514 were limited to CDC light traps, which do not provide direct measures of biting rates and 515 516 information on the timing and location of mosquito-to-human transmission. Fifth, measures of insecticide susceptibility did not utilize mosquitoes collected in the study districts; although they 517 518 were from a nearby district, susceptibility may have differed from that in Tororo District. Despite these limitations, this study benefited from the availability of prior comprehensive surveillance 519 520 data collected from the area over an extended period, resulting in important scientific findings with significant policy implications. 521

522

## 523 Conclusion

524 Our findings show that resurgence of malaria in Tororo was temporally and geographically 525 correlated with a change in IRS formulation from Actellic to Fludora Fusion and the unique 526 emergence of *An. funestus* as the predominant vector. This unprecedented increase in malaria 527 burden despite sustained and intense vector control combining repeated rounds of universal

528 LLIN distribution and IRS underscores the fragile nature of malaria control in Africa. Rotating 529 IRS formulations has been promoted as a way to limit the selection of insecticide resistance, but in this case such a rotation was associated with a dramatic malaria resurgence in Uganda. 530 531 Future changes in insecticides should take into consideration on-going surveillance that is comprehensive and includes clinical and entomological metrics, including vector species 532 composition and insecticide resistance patterns. Surveillance data should also be timely and 533 actionable, allowing for well-coordinated responses by policy makers. Indeed, the WHO Global 534 Malaria Programme now encourages the use of multiple sources of data to better understand 535 malaria risk at the sub-national level and to target interventions as part of its "High Burden High 536 537 Impact" strategy.(42)

538

# 539 Acknowledgements

540 We thank all the study team members for successfully conducting the PRISM studies over the 541 years and the Tororo and Busia district administrations for their support. We are grateful to the 542 study participants who participated in this study and their families.

543

# 544 Availability of data and materials

545 Data from the cohort study and health facility-based surveillance will be made available through

an established open-access clinical epidemiology database resource, ClinEpiDB.

- 547 <u>https://clinepidb.org/ce/app</u>
- 548

### 549 Competing interests

550 None

551

#### 552 Funding

- 553 This project was funded by the US National Institutes of Health as part of the International
- 554 Centers of Excellence in Malaria Research (ICEMR) program (U19AI089674). The funders

- 555 played no role in the design of the study; in the collection, analyses, and interpretation of data;
- in the writing of the manuscript; or in the decision to submit the manuscript for publication.

- 558 Author's contributions
- 559 **Conceptualization:** Joaniter I. Nankabirwa, Emmanuel Arinaitwe, Moses
- 560 R. Kamya, Grant Dorsey.
- 561 Data curation: John Rek, Maato Zedi, Ambrose Oruni, Peter Olwoch, Jessica Briggs, Paul
- 562 Krezanoski, Bryan Greenhouse, Grant Dorsey.
- 563 **Formal analysis:** Grant Dorsey.
- 564 **Funding acquisition:** Moses R. Kamya, Joaniter I. Nankabirwa, Grant Dorsey.
- 565 Methodology: Joaniter I. Nankabirwa, John Rek, Bryan Greenhouse, Ambrose Oruni, Moses
- 566 R. Kamya, Grant Dorsey.
- 567 **Supervision:** Joaniter I. Nankabirwa, Emmanuel Arinaitwe, Moses R. Kamya, Grant Dorsey.
- 568 Writing original draft: Moses R. Kamya, Joaniter I. Nankabirwa, Emmanuel Arinaitwe,

569 Ambrose Oruni, Grant Dorsey.

570 Writing – review & editing: all authors

- 572 Figure Legend
- 573 **Figure 1:** Map of eastern Uganda with an extract showing study sites.
- 574 **Figure 2:** Monthly trends in laboratory confirmed cases of malaria and malaria incidence from
- 575 Nagongera Health Center. PY = person years.
- 576 **Figure 3:** Monthly trends in the incidence of clinical malaria, prevalence of microscopic
- 577 parasitemia, and prevalence of microscopic or sub-microscopic parasitemia stratified by
- 578 geographic regions. Vertical bars indicate rounds of IRS (Tororo District only): yellow = Fludora
- 579 Fusion, purple = SumiShield, and orange = Actellic.
- 580 **Figure 4:** Monthly trends in the vector densities of common *Anopheles* species stratified by
- 581 geographic regions. Vertical bars indicate rounds of IRS: yellow = Fludora Fusion, purple =
- 582 SumiShield, and orange = Actellic.
- 583 **Figure 5:** Mortality of An. gambiae s.l. and An. funestus exposed to clothianidin and pirimiphos-
- 584 methyl for varying durations.
- 585

587 **References** 

588 1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of

589 malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature.

590 2015;526(7572):207-11.

591 2. World Health Organization. World malaria report 2023. Geneva: World Health

592 Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.

593 3. World Health Organization. Global technical strategy for malaria 2016–2030, 2021

<sup>594</sup> update. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

595 4. Nankabirwa JI, Rek J, Arinaitwe E, Namuganga JF, Nsobya SL, Asua V, et al. East

596 Africa International Center of Excellence for Malaria Research: Summary of Key Research

597 Findings. Am J Trop Med Hyg. 2022;107(4\_Suppl):21-32.

598 5. Nankabirwa JI, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, et al. Malaria

599 Transmission, Infection, and Disease following Sustained Indoor Residual Spraying of

Insecticide in Tororo, Uganda. Am J Trop Med Hyg. 2020;103(4):1525-33.

601 6. Epstein A, Maiteki-Sebuguzi C, Namuganga JF, Nankabirwa JI, Gonahasa S, Opigo J,

602 et al. Resurgence of malaria in Uganda despite sustained indoor residual spraying and repeated

603 long lasting insecticidal net distributions. PLoS Global Public Health.

604 2022:doi.org/10.1371/journal.pgph.0000676.

605 7. Kamya MR, Arinaitwe E, Wanzira H, Katureebe A, Barusya C, Kigozi SP, et al. Malaria

transmission, infection, and disease at three sites with varied transmission intensity in Uganda:

607 implications for malaria control. Am J Trop Med Hyg. 2015;92(5):903-12.

8. Nankabirwa JI, Bousema T, Blanken SL, Rek J, Arinaitwe E, Greenhouse B, et al.

609 Measures of malaria transmission, infection, and disease in an area bordering two districts with

and without sustained indoor residual spraying of insecticide in Uganda. PLoS ONE.

611 2022;17(12):e0279464.

9. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS
Med. 2015;12(3):e1001788.

615 10. Gillies MT, Coetzee M. A supplement to the Anophelinae of Africa South of the Sahara.
616 Johannesburg: The South African Institute for Medical Research; 1987.

Scott JA, Brogdon WG, Collins FH. Identification of single specimens of the Anopheles
gambiae complex by the polymerase chain reaction. Am J Trop Med Hyg. 1993;49(4):520-9.

12. Wirtz RA, Duncan JF, Njelesani EK, Schneider I, Brown AE, Oster CN, et al. ELISA

620 method for detecting Plasmodium falciparum circumsporozoite antibody. Bull World Health

621 Organ. 1989;67(5):535-42.

Morgan JC, Irving H, Okedi LM, Steven A, Wondji CS. Pyrethroid resistance in an
Anopheles funestus population from Uganda. PLoS ONE. 2010;5(7):e11872.

World Health Organization. Manual for monitoring insecticide resistance in mosquito
 vectors and selecting appropriate interventions. Geneva: World Health Organization; 2022.

626 Licence: CC BY-NC-SA 3.0 IGO.

15. Namuganga JF, Epstein A, Nankabirwa JI, Mpimbaza A, Kiggundu M, Sserwanga A, et
al. The impact of stopping and starting indoor residual spraying on malaria burden in Uganda.
Nat Commun. 2021;12(1):2635.

16. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsobya S, et al. Malaria in
Uganda: challenges to control on the long road to elimination: I. Epidemiology and current
control efforts. Acta Trop. 2012;121(3):184-95.

17. Lees RS, Praulins G, Lissenden N, South A, Carson J, Brown F, et al. The Residual

634 Efficacy of SumiShield 50WG and K-Othrine((R)) WG250 IRS Formulations Applied to Different

Building Materials against Anopheles and Aedes Mosquitoes. Insects. 2022;13(2).

18. Ngufor C, Fongnikin A, Rowland M, N'Guessan R. Indoor residual spraying with a

637 mixture of clothianidin (a neonicotinoid insecticide) and deltamethrin provides improved control

and long residual activity against pyrethroid resistant Anopheles gambiae sl in Southern Benin.

639 PLoS ONE. 2017;12(12):e0189575.

19. Oxborough RM, Seyoum A, Yihdego Y, Dabire R, Gnanguenon V, Wat'senga F, et al.

641 Susceptibility testing of Anopheles malaria vectors with the neonicotinoid insecticide

642 clothianidin; results from 16 African countries, in preparation for indoor residual spraying with

new insecticide formulations. Malar J. 2019;18(1):264.

644 20. Agumba S, Gimnig JE, Ogonda L, Ombok M, Kosgei J, Munga S, et al. Diagnostic dose

645 determination and efficacy of chlorfenapyr and clothianidin insecticides against Anopheles

646 malaria vector populations of western Kenya. Malar J. 2019;18(1):243.

647 21. Fongnikin A, Houeto N, Agbevo A, Odjo A, Syme T, N'Guessan R, et al. Efficacy of

648 Fludora(R) Fusion (a mixture of deltamethrin and clothianidin) for indoor residual spraying

against pyrethroid-resistant malaria vectors: laboratory and experimental hut evaluation. Parasit
Vectors. 2020;13(1):466.

Kouassi BL, Edi C, Ouattara AF, Ekra AK, Bellai LG, Gouamene J, et al. Entomological
monitoring data driving decision-making for appropriate and sustainable malaria vector control
in Cote d'Ivoire. Malar J. 2023;22(1):14.

23. Odjo EM, Salako AS, Padonou GG, Yovogan B, Adoha CJ, Adjottin B, et al. What can

be learned from the residual efficacy of three formulations of insecticides (pirimiphos-methyl,

clothianidin and deltamethrin mixture, and clothianidin alone) in large-scale in community trial in

657 North Benin, West Africa? Malar J. 2023;22(1):150.

Agossa FR, Padonou GG, Koukpo CZ, Zola-Sahossi J, Azondekon R, Akuoko OK, et al.
Efficacy of a novel mode of action of an indoor residual spraying product, SumiShield(R) 50WG
against susceptible and resistant populations of Anopheles gambiae (s.l.) in Benin, West Africa.
Parasit Vectors. 2018;11(1):293.

Marti-Soler H, Maquina M, Opiyo M, Alafo C, Sherrard-Smith E, Malheia A, et al. Effect
of wall type, delayed mortality and mosquito age on the residual efficacy of a clothianidin-based

indoor residual spray formulation (SumiShield 50WG) in southern Mozambique. PLoS ONE.2021;16(8):e0248604.

Fouet C, Ashu FA, Ambadiang MM, Tchapga W, Wondji CS, Kamdem C. Clothianidinresistant Anopheles gambiae adult mosquitoes from Yaounde, Cameroon, display reduced
susceptibility to SumiShield(R) 50WG, a neonicotinoid formulation for indoor residual spraying.
BMC Infect Dis. 2024;24(1):133.

670 27. Assatse T, Tchouakui M, Mugenzi L, Menze B, Nguiffo-Nguete D, Tchapga W, et al.

671 Anopheles funestus Populations across Africa Are Broadly Susceptible to Neonicotinoids but

with Signals of Possible Cross-Resistance from the GSTe2 Gene. Trop Med Infect Dis.

673 2023;8(5).

674 28. Ferriss E, Chaponda M, Muleba M, Kabuya JB, Lupiya JS, Riley C, et al. The Impact of

675 Household and Community Indoor Residual Spray Coverage with Fludora Fusion in a High

Malaria Transmission Setting in Northern Zambia. Am J Trop Med Hyg. 2023;109(2):248-57.

677 29. Musiime AK, Smith DL, Kilama M, Rek J, Arinaitwe E, Nankabirwa JI, et al. Impact of

vector control interventions on malaria transmission intensity, outdoor vector biting rates and

Anopheles mosquito species composition in Tororo, Uganda. Malar J. 2019;18(1):445.

680 30. Msugupakulya BJ, Urio NH, Jumanne M, Ngowo HS, Selvaraj P, Okumu FO, et al.

681 Changes in contributions of different Anopheles vector species to malaria transmission in east

and southern Africa from 2000 to 2022. Parasit Vectors. 2023;16(1):408.

683 31. Akoton R, Sovegnon PM, Djihinto OY, Medjigbodo AA, Agonhossou R, Saizonou HM, et

al. Vectorial competence, insecticide resistance in Anopheles funestus and operational

685 implications for malaria vector control strategies in Benin Republic. Malar J. 2023;22(1):385.

686 32. Aschale Y, Getachew A, Yewhalaw D, De Cristofaro A, Sciarretta A, Atenafu G.

687 Systematic review of sporozoite infection rate of Anopheles mosquitoes in Ethiopia, 2001-2021.

688 Parasit Vectors. 2023;16(1):437.

689 33. Choi KS, Christian R, Nardini L, Wood OR, Agubuzo E, Muleba M, et al. Insecticide

690 resistance and role in malaria transmission of Anopheles funestus populations from Zambia and

691 Zimbabwe. Parasit Vectors. 2014;7:464.

692 34. Djouaka R, Riveron JM, Yessoufou A, Tchigossou G, Akoton R, Irving H, et al. Multiple

693 insecticide resistance in an infected population of the malaria vector Anopheles funestus in

Benin. Parasit Vectors. 2016;9:453.

695 35. Menze BD, Riveron JM, Ibrahim SS, Irving H, Antonio-Nkondjio C, Awono-Ambene PH,

696 et al. Multiple Insecticide Resistance in the Malaria Vector Anopheles funestus from Northern

697 Cameroon Is Mediated by Metabolic Resistance Alongside Potential Target Site Insensitivity

698 Mutations. PLoS ONE. 2016;11(10):e0163261.

699 36. Mzilahowa T, Chiumia M, Mbewe RB, Uzalili VT, Luka-Banda M, Kutengule A, et al.

700 Increasing insecticide resistance in Anopheles funestus and Anopheles arabiensis in Malawi,

701 2011-2015. Malar J. 2016;15(1):563.

702 37. Pinda PG, Eichenberger C, Ngowo HS, Msaky DS, Abbasi S, Kihonda J, et al.

703 Comparative assessment of insecticide resistance phenotypes in two major malaria vectors,

Anopheles funestus and Anopheles arabiensis in south-eastern Tanzania. Malar J.

705 2020;19(1):408.

38. Takken W, Verhulst NO. Host preferences of blood-feeding mosquitoes. Annu Rev
Entomol. 2013;58:433-53.

39. Omondi S, Kosgei J, Musula G, Muchoki M, Abong'o B, Agumba S, et al. Late morning

biting behaviour of Anopheles funestus is a risk factor for transmission in schools in Siaya,

710 western Kenya. Malar J. 2023;22(1):366.

40. Raouf S, Mpimbaza A, Kigozi R, Sserwanga A, Rubahika D, Katamba H, et al.

712 Resurgence of Malaria Following Discontinuation of Indoor Residual Spraying of Insecticide in

an Area of Uganda With Previously High-Transmission Intensity. Clin Infect Dis.

714 2017;65(3):453-60.

- 715 41. Namayanja C, Eregu EEI, Ongodia P, Okalebo CB, Okiror W, Okello F, et al. Unusual
- clinical spectra of childhood severe malaria during malaria epidemic in eastern Uganda: a
- 717 prospective study. Malar J. 2023;22(1):169.
- 42. World Health Organization. Malaria surveillance, monitoring & evaluation: a reference
- 719 manual. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO..



Figure 2



Month and year

Figure 3







Days Post exposure